EmaxHealth

Health knowledge and news provided by doctors.

Ads by Google

HIV AIDS

Newly Approved HIV Drug Shows Great Promise

AIDS Institute is encouraged with FDA's approval of the first new non-nucleoside reverse transcriptase inhibitor (NNRTI) in nearly a decade. TMC125/etravirine was developed by Tibotec Pharmaceuticals, Ltd. and will be marketed in the U.S. by Tibotec Therapeutics as Intelence, a division of Ortho Biotech Products, L.P. The company announced introductory pricing for the new NNRTI at $21.80 per day, which is substantially lower than other recently introduced antiretrovirals.

conditions: 

Pages